Assembly Biosciences (ASMB) Competitors

$29.74 -1.19 (-3.85%)

Closing price 04:00 PM Eastern

Extended Trading

$29.72 -0.02 (-0.07%)

As of 04:10 PM Eastern

ASMB vs. PRGO, OMER, PCRX, CPIX, and LLY

Should you be buying Assembly Biosciences stock or one of its competitors? The main competitors of Assembly Biosciences include Perrigo (PRGO), Omeros (OMER), Pacira BioSciences (PCRX), Cumberland Pharmaceuticals (CPIX), and Eli Lilly and Company (LLY). These companies are all part of the "pharmaceuticals" industry.

How does Assembly Biosciences compare to Perrigo?

Perrigo (NYSE:PRGO) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Assembly Biosciences has lower revenue, but higher earnings than Perrigo. Assembly Biosciences is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.38	-$1.43B	-$13.10	N/A
Assembly Biosciences	$72.30M	6.54	-$6.12M	-$0.74	N/A

Perrigo has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500.

Assembly Biosciences has a net margin of -8.98% compared to Perrigo's net margin of -43.50%. Perrigo's return on equity of 9.96% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-43.50%	9.96%	3.90%
Assembly Biosciences	-8.98%	-4.70%	-3.31%

Perrigo currently has a consensus price target of $19.33, indicating a potential upside of 65.07%. Assembly Biosciences has a consensus price target of $42.75, indicating a potential upside of 43.75%. Given Perrigo's higher possible upside, research analysts clearly believe Perrigo is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Perrigo had 2 more articles in the media than Assembly Biosciences. MarketBeat recorded 11 mentions for Perrigo and 9 mentions for Assembly Biosciences. Perrigo's average media sentiment score of 0.57 beat Assembly Biosciences' score of 0.44 indicating that Perrigo is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Assembly Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

95.9% of Perrigo shares are owned by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are owned by institutional investors. 0.4% of Perrigo shares are owned by insiders. Comparatively, 5.3% of Assembly Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Perrigo and Assembly Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Assembly Biosciences compare to Omeros?

Omeros (NASDAQ:OMER) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

48.8% of Omeros shares are owned by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are owned by institutional investors. 12.9% of Omeros shares are owned by company insiders. Comparatively, 5.3% of Assembly Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Omeros has a beta of 2.66, meaning that its stock price is 166% more volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.

Omeros has a net margin of 0.00% compared to Assembly Biosciences' net margin of -8.98%. Assembly Biosciences' return on equity of -4.70% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-72.14%	59.71%
Assembly Biosciences	-8.98%	-4.70%	-3.31%

In the previous week, Assembly Biosciences had 5 more articles in the media than Omeros. MarketBeat recorded 9 mentions for Assembly Biosciences and 4 mentions for Omeros. Omeros' average media sentiment score of 0.48 beat Assembly Biosciences' score of 0.44 indicating that Omeros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Assembly Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Omeros currently has a consensus price target of $40.33, indicating a potential upside of 185.44%. Assembly Biosciences has a consensus price target of $42.75, indicating a potential upside of 43.75%. Given Omeros' stronger consensus rating and higher probable upside, equities analysts clearly believe Omeros is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Omeros has higher earnings, but lower revenue than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	-$0.50	N/A
Assembly Biosciences	$72.30M	6.54	-$6.12M	-$0.74	N/A

Summary

Omeros beats Assembly Biosciences on 12 of the 16 factors compared between the two stocks.

How does Assembly Biosciences compare to Pacira BioSciences?

Assembly Biosciences (NASDAQ:ASMB) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 5.3% of Assembly Biosciences shares are held by company insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Assembly Biosciences has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500.

Pacira BioSciences has a net margin of 0.70% compared to Assembly Biosciences' net margin of -8.98%. Pacira BioSciences' return on equity of 10.24% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-8.98%	-4.70%	-3.31%
Pacira BioSciences	0.70%	10.24%	5.47%

In the previous week, Assembly Biosciences had 4 more articles in the media than Pacira BioSciences. MarketBeat recorded 9 mentions for Assembly Biosciences and 5 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 0.69 beat Assembly Biosciences' score of 0.44 indicating that Pacira BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assembly Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pacira BioSciences	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Assembly Biosciences presently has a consensus price target of $42.75, indicating a potential upside of 43.75%. Pacira BioSciences has a consensus price target of $29.40, indicating a potential upside of 27.00%. Given Assembly Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Assembly Biosciences is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Pacira BioSciences has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$72.30M	6.54	-$6.12M	-$0.74	N/A
Pacira BioSciences	$726.41M	1.25	$7.03M	$0.12	192.92

Summary

Pacira BioSciences beats Assembly Biosciences on 10 of the 16 factors compared between the two stocks.

How does Assembly Biosciences compare to Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are held by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are held by insiders. Comparatively, 5.3% of Assembly Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cumberland Pharmaceuticals has higher earnings, but lower revenue than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Cumberland Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	1.57	-$2.84M	-$0.49	N/A
Assembly Biosciences	$72.30M	6.54	-$6.12M	-$0.74	N/A

Cumberland Pharmaceuticals has a beta of -0.06, meaning that its share price is 106% less volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500.

Assembly Biosciences has a consensus price target of $42.75, indicating a potential upside of 43.75%. Given Assembly Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Assembly Biosciences is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Assembly Biosciences has a net margin of -8.98% compared to Cumberland Pharmaceuticals' net margin of -17.60%. Assembly Biosciences' return on equity of -4.70% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-17.60%	-11.47%	-4.25%
Assembly Biosciences	-8.98%	-4.70%	-3.31%

In the previous week, Assembly Biosciences had 3 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 9 mentions for Assembly Biosciences and 6 mentions for Cumberland Pharmaceuticals. Assembly Biosciences' average media sentiment score of 0.44 beat Cumberland Pharmaceuticals' score of 0.27 indicating that Assembly Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cumberland Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Assembly Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Assembly Biosciences beats Cumberland Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Assembly Biosciences compare to Eli Lilly and Company?

Assembly Biosciences (NASDAQ:ASMB) and Eli Lilly and Company (NYSE:LLY) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Assembly Biosciences currently has a consensus price target of $42.75, suggesting a potential upside of 43.75%. Eli Lilly and Company has a consensus price target of $1,218.33, suggesting a potential upside of 28.51%. Given Assembly Biosciences' higher probable upside, equities analysts plainly believe Assembly Biosciences is more favorable than Eli Lilly and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Eli Lilly and Company	1 Sell rating(s)	4 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	2.87

19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are held by institutional investors. 5.3% of Assembly Biosciences shares are held by company insiders. Comparatively, 0.1% of Eli Lilly and Company shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Assembly Biosciences has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Eli Lilly and Company has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500.

Eli Lilly and Company has a net margin of 34.98% compared to Assembly Biosciences' net margin of -8.98%. Eli Lilly and Company's return on equity of 105.77% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-8.98%	-4.70%	-3.31%
Eli Lilly and Company	34.98%	105.77%	23.76%

In the previous week, Eli Lilly and Company had 167 more articles in the media than Assembly Biosciences. MarketBeat recorded 176 mentions for Eli Lilly and Company and 9 mentions for Assembly Biosciences. Eli Lilly and Company's average media sentiment score of 0.91 beat Assembly Biosciences' score of 0.44 indicating that Eli Lilly and Company is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assembly Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eli Lilly and Company	101 Very Positive mention(s)	37 Positive mention(s)	20 Neutral mention(s)	10 Negative mention(s)	2 Very Negative mention(s)	Positive

Eli Lilly and Company has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$72.30M	6.54	-$6.12M	-$0.74	N/A
Eli Lilly and Company	$65.18B	13.70	$20.64B	$28.15	33.68

Summary

Eli Lilly and Company beats Assembly Biosciences on 14 of the 17 factors compared between the two stocks.

Get Assembly Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASMB vs. The Competition

Export

Metric	Assembly Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$491.56M	$6.04B	$6.18B	$12.24B
Dividend Yield	N/A	0.72%	2.78%	5.24%
P/E Ratio	-270.34	6.68	28.73	27.26
Price / Sales	6.54	29.65	507.60	64.06
Price / Cash	N/A	8.39	43.30	53.97
Price / Book	2.28	4.03	10.00	6.83
Net Income	-$6.12M	$118.49M	$3.54B	$332.87M
7 Day Performance	N/A	N/A	N/A	0.09%
1 Month Performance	1.33%	5.42%	4.68%	7.37%
1 Year Performance	155.06%	136.55%	40.48%	41.09%

Assembly Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASMB Assembly Biosciences	2.0621 of 5 stars	$29.74 -3.8%	$42.75 +43.7%	+146.2%	$491.56M	$72.30M	N/A	100	News Coverage Earnings Report
PRGO Perrigo	4.6052 of 5 stars	$11.81 +4.6%	$19.33 +63.8%	-55.4%	$1.63B	$4.25B	N/A	8,100	Earnings Report
OMER Omeros	2.3452 of 5 stars	$14.64 +0.5%	$40.33 +175.5%	+130.6%	$1.06B	N/A	N/A	210	News Coverage
PCRX Pacira BioSciences	3.8712 of 5 stars	$25.58 +1.8%	$30.25 +18.3%	-6.0%	$1.04B	$726.41M	170.51	720
CPIX Cumberland Pharmaceuticals	0.1998 of 5 stars	$4.25 +0.8%	N/A	-5.9%	$63.51M	$44.52M	N/A	80	Earnings Report Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASMB) was last updated on 5/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Assembly Biosciences (ASMB) Competitors

ASMB vs. PRGO, OMER, PCRX, CPIX, and LLY

How does Assembly Biosciences compare to Perrigo?

Summary

How does Assembly Biosciences compare to Omeros?

Summary

How does Assembly Biosciences compare to Pacira BioSciences?

Summary

How does Assembly Biosciences compare to Cumberland Pharmaceuticals?

Summary

How does Assembly Biosciences compare to Eli Lilly and Company?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASMB vs. The Competition

Assembly Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Assembly Biosciences (ASMB) Competitors

ASMB vs. PRGO, OMER, PCRX, CPIX, and LLY

How does Assembly Biosciences compare to Perrigo?

Which has better earnings & valuation, PRGO or ASMB?

Which has more volatility and risk, PRGO or ASMB?

Is PRGO or ASMB more profitable?

Do analysts prefer PRGO or ASMB?

Does the media favor PRGO or ASMB?

Do institutionals & insiders believe in PRGO or ASMB?

Summary

How does Assembly Biosciences compare to Omeros?

Do insiders and institutionals believe in OMER or ASMB?

Which has more volatility & risk, OMER or ASMB?

Is OMER or ASMB more profitable?

Does the media refer more to OMER or ASMB?

Do analysts rate OMER or ASMB?

Which has preferable valuation and earnings, OMER or ASMB?

Summary

How does Assembly Biosciences compare to Pacira BioSciences?

Do institutionals and insiders have more ownership in ASMB or PCRX?

Which has more risk and volatility, ASMB or PCRX?

Is ASMB or PCRX more profitable?

Does the media prefer ASMB or PCRX?

Do analysts prefer ASMB or PCRX?

Which has higher valuation and earnings, ASMB or PCRX?

Summary

How does Assembly Biosciences compare to Cumberland Pharmaceuticals?

Do insiders & institutionals have more ownership in CPIX or ASMB?

Which has stronger earnings and valuation, CPIX or ASMB?

Which has more volatility & risk, CPIX or ASMB?

Do analysts prefer CPIX or ASMB?

Is CPIX or ASMB more profitable?

Does the media prefer CPIX or ASMB?

Summary

How does Assembly Biosciences compare to Eli Lilly and Company?

Do analysts recommend ASMB or LLY?

Do insiders and institutionals have more ownership in ASMB or LLY?

Which has more risk & volatility, ASMB or LLY?

Is ASMB or LLY more profitable?

Does the media refer more to ASMB or LLY?

Which has higher valuation & earnings, ASMB or LLY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASMB vs. The Competition

Assembly Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools